Infineon Undervalued Former Chip Unit Qimonda by $1.88 Billion, Court Expert Says
By David Sachs
Infineon Technologies undervalued its defunct memory-chip business, Qimonda, by 1.72 billion euros ($1.88 billion) during its carve-out for a public listing, the German semiconductor company said, citing a court-appointed expert's decision in a legal dispute spanning 14 years.
Qimonda, a memory-chip company in which Infineon owned a majority stake, filed for insolvency in 2009, three years after its public listing. Insolvency administrator Michael Jaffe later sued Infineon in Munich district court, claiming that Qimonda was entitled to a reimbursement because Infineon omitted certain declarations during the carve-out.
Infineon said late Monday that the expert pegged Qimonda's foreign business at minus EUR1.045 billion and its domestic business at minus EUR72.3 million, but that the sum does not equate to a liability for Infineon.
"The submission of the opinion represents an interim step in the pending legal dispute," the company said. "The amount of potential liability of Infineon depends on other aspects."
Jaffe did not immediately respond to a request for comment.
Infineon said it is unclear when a decision by the court will be reached.
As of Sept. 30, Infineon said it has recognized EUR212 million in provisions related to the lawsuit with Qimonda.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
January 09, 2024 02:52 ET (07:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks